Hodgkin’s Lymphoma (HL) is defined as the cancer of the lymph tissue,
which is part of our immune system. The exact etiology of HL is unknown.
However, the risk of developing the condition is increased if a person suffers
from a medical condition that weakens the immune system. In HL, cells in the
lymphatic system grow unusually and may spread beyond the lymphatic system. The
infection-fighting properties of the lymphocytes are lost, making the person
more susceptible to infection. The main treatments used are chemotherapy,
followed by radiotherapy or chemotherapy alone. Generally surgery is not used
as a treatment for the condition.
Analysts forecast the Global Hodgkin’s
Lymphoma Therapeutics market will grow at a CAGR
of 6.84 percent over the period 2013-2018.
The Report recognizes the following companies as the key players in the
Global Hodgkins Lymphoma Therapeutics Market :
There has been an increase in awareness of Hodgkin's lymphoma among
patients and physicians. Enhanced patient and physician awareness is expected
to lead to earlier disease diagnosis and treatment. The acceptability of
Hodgkin's lymphoma drugs is expected to rise because of the increasing public
awareness. Raising general awareness about Hodgkin's lymphoma has led to an
increase in research funding and support for clinical and support services. For
instance, September 15 is celebrated as WLAD by the LRF. The program was
initiated to make people more aware about both Hodgkin's lymphoma and NHL in
terms of symptom recognition, early diagnosis, and treatment
Covered in this
Report
The Global Hodgkin’s Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
The Global Hodgkin’s Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
Global Hodgkin’s Lymphoma Therapeutics Market 2014-2018, has been
prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas, and the EMEA and APAC regions; it also
covers the Global Hodgkin’s Lymphoma Therapeutics market landscape and its
growth prospects in the coming years. The report also includes a discussion of
the key vendors operating in this market.
According to the report the Global Hodgkin's Lymphoma Therapeutics market
is driven by several factors. One of the main drivers in this market is the
improved diagnostic techniques. Improved diagnostic techniques have led to the
treatment of Hodgkin's lymphoma in an aggressive way and have driven revenue
growth in a positive direction. Improvement in the diagnosis leads to the early
detection and treatment of the disease.
Further, the report states that the Global Hodgkin's Lymphoma
Therapeutics market is inhibited by some serious challenges. One of the main
challenges is the high cost of Hodgkin's lymphoma treatment. Despite the
numerous benefits, the high cost of treatment options hinders the acceptability
among patients. Many patients do not have the required budget for investing in
high-cost treatment options.
